Summary
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
History
Mydecine Innovations Group was founded in 2018 with a commitment to introducing the world to the power of nature-based solutions for better health and well-being. The company is the first of its kind to dedicate its focus on researching and developing new therapeutic approaches to supporting overall health utilizing mushrooms and fungi.
Mission
Mydecine stands committed to innovating science-backed solutions and researches emerging therapeutic approaches centered around the power of fungi. Our mission is to develop and offer accessible, natural solutions to improve the lives of our customers and further the field of mycology and its potential health impacts globally.
Vision
Mydecine’s vision is to become a global leader in the research and development of fungi-based health solutions, and to bring the power of nature to the world to help all people achieve and maintain their highest level of health and well-being.
Key Team
Mr. Sanford M. Stein (Chief Compliance Officer, Gen. Counsel & Corp. Sec.)
Dr. Rakesh Jetly FRCPC, M.D. (Chief Medical Officer)
Mr. John Charles Ross CA, CPA, M.B.A. (Chief Financial Officer)
Morgan Kervitsky (Director of Marketing)
Mr. Michel Rudolphie (Pres of the European Operations)
Mr. William Cook (Interim CEO & Technical Director of Mindleap Health Inc.)
Recognition and Awards
Mydecine Innovations Group is the proud winner of the 2020 NEXTY Award for Best New Supplement
References
